XmAb13676

Phase 1Biologic

XXencor, Inc.

XmAb13676 is one of 38 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Idiopathic Inflammatory MyopathyActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Idiopathic Inflammatory MyopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Cimzia

UCB

Preclinical

30 3

Enbrel

IImmunex

Preclinical

64 4

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 5

Actos

Takeda

Preclinical

2 6

Celexa

AbbVie

Preclinical

1 7

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 8

Rituxan

Pfizer

Preclinical

7 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Idiopathic Inflammatory Myopathy

NCT07284797

Q2 2028

Phase 1Recruiting

Rheumatoid Arthritis

NCT07230353

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis

Recruiting·XXencor, Inc.·Phase 1·NCT07230353·47 enrolled

Hematologic Malignancies1 trial

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Completed·XXencor, Inc.·Phase 1·NCT02924402·154 enrolled

Idiopathic Inflammatory Myopathy1 trial

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)

Not yet recruiting·XXencor, Inc.·Phase 1·NCT07284797·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for XmAb13676. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XmAb13676 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XmAb13676. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: XXencor, Inc.

XmAb13676

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Hematologic Malignancies1 trial

Idiopathic Inflammatory Myopathy1 trial

References

Drug Info

Quick Facts

Related News